Cognizant Teams Up with Organon to Speed Delivery of Pharmaceutical Products and Improve Women's Healthcare

2022-07-21

Organon's Manufacturing Site Efficiencies Expected to Improve Supply Chain Management and Speed Healthcare Product Delivery

TEANACK, N.J., July 21, 2022 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) today announced it has signed a new multi-year agreement with Organon (NYSE: OGN), a global women's health company, to help improve the company's delivery of healthcare products and crucial medicinal supply chain management.

Through the agreement, Cognizant will help scale Organon's healthcare business by delivering full-stack industrial technology support for the company's global pharmaceutical manufacturing sites in the United Kingdom, Netherlands, Belgium and Indonesia. This includes managing Organon's manufacturing systems with SAP's S4/HANA enterprise application suite. Additionally, by providing remote and onsite support teams to increase real-time visibility of the manufacturing process and ensure pharmaceutical development continuity, Cognizant seeks to help Organon enhance supply chain oversight, increase medicinal yields, reduce cycle times and get products to patients faster.

"Technology is an important pillar of differentiation for Organon in fulfilling our mission of becoming the world's leading women's health company," said Rachel Stahler, Chief Information Officer at Organon. "By partnering with Cognizant, we have teamed up with one of world's top technology and professional services companies to advance our digital ambitions and capabilities, along with speeding access to important therapies for women everywhere."

"Our work with Organon to align its pharmaceutical development with Industry 4.0 principles is crucial to supporting women's health in an efficient, expedient and compliant approach," said Surya Gummadi, Cognizant's SVP of Global Health Sciences and SVP, Americas. "Partnerships like ours will help create new opportunities for companies to transform their businesses and deliver quality healthcare at scale."

Today, Cognizant works with each of the world's top 30 pharmaceutical companies. Its 2019 acquisition of Zenith Technologies has enabled Cognizant to become one of the only global organizations capable of providing end-to-end support for pharmaceutical manufacturing systems. The combined Cognizant-Zenith Technologies expertise delivers a range of Industry 4.0 capabilities, including machine sensor and controller instrumentation, supervisory control, data acquisition and automation. Most of Organon's manufacturing and supply program will be managed and supported by leveraging Cognizant-Zenith capabilities.

About Cognizant

Cognizant (Nasdaq: CTSH) engineers modern businesses. We help our clients modernize technology, reimagine processes and transform experiences so they can stay ahead in our fast-changing world. Together, we're improving everyday life. See how at www.cognizant.com or @cognizant.

SOURCE Cognizant

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构

Mehiläinen Hoivapalvelut Oy